Home News

ROVI and the EIB agreement

ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies

Thu, 21/12/2017 - 18:33 0 min
No votes yet
 
Related
ROVI acquires rights to Dexchlorpheniramine Maleate in the Spanish and French...
Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”) has reached an agreement with a subsidiary of MSD (“MSD”) whereby ROVI acquires certain...
2 min
15/02/2019
ROVI acquires Falithrom® for the German market
Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”) has announced the purchase of Falithrom®, which was owned by Hexal AG (“Hexal”), a company...
1 min
09/01/2019
9M 2018 Results presentation
0 min
06/11/2018